Hairy cell leukemia (HCL) usually presents with peripheral cytopenias, diffuse marrow infiltration, and splenomegaly. This chronic lymphoproliferative disorder is not typically associated with lymphadenopathy or mass lesions. We report a case of HCL first treated by splenectomy, followed by several years of interferon therapy. Twenty-five years later, the patient presented with weight loss, fatigue, and a large PET-avid mass surrounding the head of the pancreas. Fine-needle aspiration was pursued to investigate the unusual and infiltrative appearance of the lesion, which was suggestive of another primary malignancy. Cytology smears showed discohesive lymphoid cells with round nuclei and delicate cytoplasmic projections. Flow cytometry confirmed the presence of a clonal B-cell population with bright expression of CD20 as well as CD25 and CD103, diagnostic of HCL. This is the first report of HCL presenting as a peripancreatic mass. The importance of correlation with radiology and clinical history is emphasized when evaluating such lesions.

1.
Summers TA, Jaffe ES: Hairy cell leukemia diagnostic criteria and differential diagnosis. Leuk Lymphoma 2011;52(suppl 2):6–10.
2.
Tadmor T, Polliack A: Unusual clinical manifestations, rare sites of involvement, and the association of other disorders with hairy cell leukemia. Leuk Lymphoma 2011;52(suppl 2):57–61.
3.
Al-Za’abi AM, Boerner SL, Geddie W: Hairy cell leukemia presenting as a discrete liver mass: diagnosis by fine needle aspiration biopsy. Diagn Cytopathol 2008;36:128–132.
4.
Kaw YT, Artymyshyn RL, Schichman SA, Salhany KE: Recurrent hairy cell leukemia presenting as a large mesenteric mass diagnosed by fine needle aspiration cytology: a case report. Acta Cytol 1994,38:267–270.
5.
Moriarty AT, Schwenk GR Jr, Chua G: Splenic fine needle aspiration biopsy in the diagnosis of lymphoreticular diseases: a report of four cases. Acta Cytol 1993;37:191–196.
6.
Pinto RG, Rocha PD, Vernekar JA: Fine needle aspiration of the spleen in hairy cell leukemia: a case report. Acta Cytol 1995;39:777–780.
7.
Goodman GR, Burian C, Koziol JA, Saven A: Extended follow-up of patients with hairy cell leukemia after treatment with cladribine: J Clin Oncol 2003;21:891–896.
8.
Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM: Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood 1998;92:1160–1164.
9.
Emilia G, Luppi M, Gandini G, Bertesi M, Torelli G: Hairy cell leukemia, second cancer and occupational risk. Br J Haematol 1995;78:518.
10.
Bethel KJ, Sharpe RW: Pathology of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003;16:15–31.
11.
Arnalich F, Camacho J, Jimenez C, Lahoz C, Patrón M: Occurrence of immunoblastic B-cell lymphoma in hairy cell leukemia. Cancer 1987;59:161–164.
12.
Downing JR, Grossi CE, Smedberg CT, Burrows PD: Diffuse large cell lymphoma in a patient with hairy cell leukemia: immunoglobulin gene analysis reveals separate clonal origins. Blood 1986;67:739–744.
13.
Lopera GA, Alvarez OA, Lee M: Large cell lymphoma of the colon presenting as a second malignancy in a patient with hairy cell leukemia. J Clin Gastroenterol 1995;21:259–260.
14.
Franssila KO: Coincidental hairy cell leukemia and large cell malignant lymphoma. Arch Pathol Lab Med 1979;103:437–439.
15.
Sanyal R, Remer EM: Radiology of the retroperitoneum: case-based review. AJR Am J Roentgenol 2009;192:S112–S117.
16.
Mercieca J, Matutes E, Moskovic E, MacLennan K, Matthey F, Costello C, Behrens J, Basu S, Roath S, Fairhead S, Flandrin G, Brizard A, Catovsky D: Massive abdominal lymphadenopathy in hairy cell leukaemia: a report of 12 cases. Br J Haematol 1992;82:547–554.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.